{"id":"azilsartan-trimethylethanolamine","phase":"phase_1","safety":{"boxedWarning":"Can cause fetal harm when administered to pregnant women. Discontinue as soon as possible once pregnancy is detected.","boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["Dizziness","Diarrhea","Fatigue"],"contraindications":["Pregnancy","Concomitant use with aliskiren in patients with diabetes"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT01985152"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"Azilsartan Trimethylethanolamine is a small molecule that acts as a Type-1 angiotensin II receptor antagonist. It is used in a Phase I study to evaluate its single-dose pharmacokinetics in healthy volunteers.","brandName":"Azilsartan Trimethylethanolamine","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","mechanism":{"target":"Angiotensin II Type 1 (AT1) Receptor","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Azilsartan selectively blocks the AT1 receptor, preventing angiotensin II from binding and causing vasoconstriction. This blockade reduces peripheral vascular resistance and decreases aldosterone secretion, leading to reduced blood pressure and improved cardiovascular outcomes.","oneSentence":"Blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123130,"model":"claude-sonnet-4-5-20250929"},"companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","competitors":[{"name":"Olmesartan medoxomil","brand":"Benicar","company":"Daiichi Sankyo","rationale":"Angiotensin II receptor blocker for hypertension treatment"},{"name":"Telmisartan","brand":"Micardis","company":"Boehringer Ingelheim","rationale":"ARB with long half-life for hypertension management"},{"name":"Valsartan","brand":"Diovan","company":"Novartis","rationale":"Widely used ARB for hypertension and heart failure"}],"description":"Azilsartan Trimethylethanolamine is a Phase 1 investigational formulation being developed by Jiangsu Hansoh Pharmaceutical. It is a salt form of azilsartan, an angiotensin II receptor blocker (ARB) used for treating hypertension by blocking the AT1 receptor and reducing blood pressure.","genericName":"Azilsartan Trimethylethanolamine","indications":{"approved":[{"status":"investigational","condition":"Hypertension","patientPopulation":"Adult"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}